TCTMD

‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent

WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
TCTMD

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Physicians in the United States will now have access to the first commercially available “dissolving” stent for the treatment of patients with coronary artery disease following today’s US Food and ...
MD&M East

FDA Approval Makes Abbott's Absorb a First—Now What?

Absorb, Abbott's coronary stent system made to fully dissolve in the patient's body, has finally been approved by FDA. The agency's nod comes as the device is already available in more than 100 ...
MD&M East

Abbott to Stop Selling Absorb

Little more than a year after receiving FDA approval for its Absorb Bioresorbable Vascular Scaffold (BVS), Abbott has announced it will stop selling the device. The worldwide discontinuation of sales, ...